Trials / Unknown
UnknownNCT04343859
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors
A Phase I Clinical Trial of IMMH-010 in Patients With Advanced Malignant Solid Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- Sponsor
- Tianjin Chasesun Pharmaceutical Co., LTD · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I study of IMMH-010 in patients with advanced malignant solid tumors
Detailed description
To evaluate the safety and tolerability of single-dose and multi-dose IMMH-010 in patients with advanced solid tumors, et al.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMMH-010 | After tolerance study, 360mg and above IMMH-010 will be administered in Dose expansion study. |
Timeline
- Start date
- 2020-05-14
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
- First posted
- 2020-04-13
- Last updated
- 2023-11-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04343859. Inclusion in this directory is not an endorsement.